IDMC Recommends Continuation of REGAL Trial of Galinpepimut-S in AML
An independent data monitoring committee has recommended that the phase 3 REGAL trial examining galinpepimut-S in patients with acute myeloid leukemia continue as planned without modifications.
Angelos Stergiou Sellas Life Sciences Group Inc Life Sciences Life Sciences Group Sciences Group Patients With Acute Myeloid Leukemia
Source: onclive.com